Prophylaxis News and Research

RSS

Malaria cases in the U.S. rising due to international travel, inadequate use of prevention methods

The number of malaria cases in the United States is rising, a trend that can be linked to the increasing amount of international travel and inadequate use of prevention methods.

9 Dec 2013

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.

9 Dec 2013

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Biogen Idec announced today that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application (BLA) for ALPROLIX, the company's investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.

2 Dec 2013

New NIH guidelines for managing opportunistic infections in children with HIV

Sharon Nachman, MD, a pediatric HIV and infectious diseases specialist at Stony Brook Children's Hospital, is a co-author of new National Institutes of Health (NIH)-issued guidelines for the prevention, treatment and management of opportunistic infections in HIV-exposed and HIV-infected children. The 2013 guidelines shed light on the most effective way to treat dangerous and deadly infections such as pneumonia or tuberculosis that can strike immunosuppressed pediatric HIV patients.

27 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

9 Oct 2013

Personalised therapy can reduce risk of cardiac disease among diabetes patients

600,000 to 800,000 Austrians suffer from diabetes mellitus. Thanks to the biomarker known as NT-proBNP (a hormone specific to the heart), the sub-group of people who are at increased risk of cardiovascular disease can be determined even though their hearts appear to be healthy.

8 Oct 2013

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Janssen R&D Ireland announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis against HIV infection.

25 Sep 2013

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV).

17 Sep 2013

GIQuIC expands endoscopic quality registry to include upper GI endoscopy

The GI Quality Improvement Consortium announces the expansion of its endoscopic quality registry to include upper GI endoscopy and related quality measures. GIQuIC, a quality benchmarking registry co-sponsored by the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy, provides reliable and relevant measures of endoscopic quality that give physicians meaningful information they can use to improve patient care.

10 Sep 2013

Acacia Pharma raises $23.5 million in Series B financing

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S.

3 Sep 2013

Researchers outline recommendations to lower costs and lead to better care for patients

Medical organizations are participating in a campaign to help clinicians and patients avoid wasteful and sometimes harmful medical interventions. Recently, experts in pediatric and adult health from diverse geographic locations of the United States and from a mix of academic and non- academic settings shared their experiences, consulted their colleagues, and analyzed numerous studies in the medical literature to determine the top recommendations for improving healthcare value.

20 Aug 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B.

17 Aug 2013

Research roundup: The health of the U.S.; doctors aren't paid to talk; savings from high-deductible plans

Understanding the major health problems in the United States and how they are changing over time is critical for informing national health policy. ... From 1990 to 2010, the United States made substantial progress in improving health. Life expectancy at birth and [healthy life expectancy] increased, all-cause death rates at all ages decreased, and age-specific rates of years lived with disability remained stable.

17 Aug 2013

Study provides efficient strategy for prevention of rotavirus infection

For children and immune compromised adults in developing countries, diarrheal disease induced by rotavirus can be life threatening. Current rotaviral vaccines are highly effective in the Western world, but are not as effective in developing countries.

9 Aug 2013

Updated United States Public Health Service guidelines for management of occupational exposure to HIV

New guidelines from the United States Public Health Service update the recommendations for the management of healthcare personnel with occupational exposure to HIV and use of postexposure prophylaxis.

7 Aug 2013

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division

Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.

2 Aug 2013

Prophylaxis News and Research

Malaria cases in the U.S. rising due to international travel, inadequate use of prevention methods

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

New NIH guidelines for managing opportunistic infections in children with HIV

Merck announces approval of NOXAFIL delayed-release tablets by FDA

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Personalised therapy can reduce risk of cardiac disease among diabetes patients

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

GIQuIC expands endoscopic quality registry to include upper GI endoscopy

Acacia Pharma raises $23.5 million in Series B financing

Researchers outline recommendations to lower costs and lead to better care for patients

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Research roundup: The health of the U.S.; doctors aren't paid to talk; savings from high-deductible plans

Study provides efficient strategy for prevention of rotavirus infection

Updated United States Public Health Service guidelines for management of occupational exposure to HIV

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News